Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Candidate pharmacogenetic signals at CCL2 and ITPA associated with JAK inhibitor response in Taiwanese rheumatoid arthritis.

Clinical and experimental rheumatology - 1 Sept 2026

Hsieh Ting-Yu, Chen I-Chieh, Wu Ting-Shuan, Lo Sheng-Min, Kao Chung-Mao, Chen Yen-Ju, Huang Wen-Nan, Liu Feng-Cheng, Chen Yi-Ming

Abstract excerpt

OBJECTIVES: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterised by persistent synovial inflammation. Janus kinase inhibitors (JAKi) are effective targeted therapies for RA, yet clinical responses vary. We aimed to identify genetic predictors of JAKi effectiveness in Taiwanese patients with RA. METHODS: In this retrospective study, 275 RA patients treated with tofacitinib, baricitinib, or...

Read the complete abstract on PubMed

Topics

Humans
Chemokine CCL2
Arthritis, Rheumatoid
Female
Taiwan
Janus Kinase Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Polymorphism, Single Nucleotide

Male

Middle Aged

Retrospective Studies

Treatment Outcome

Pyrimidines

Piperidines

Pyrazoles

Sulfonamides

Heterocyclic Compounds, 3-Ring

Azetidines

Aged

Source

Identifiers

PMID: 41841677
DOI: 10.55563/clinexprheumatol/17yc25

Genes

ITPA
CCL2
ACR
CD14

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Candidate pharmacogenetic signals at CCL2 and ITPA associated with JAK inhibitor response in Taiwanese rheumatoid arthritis.PMID 41841677Read ↗

The Clinical Response of Upadacitinib and Risankizumab is Associated with Reduced Inflammatory Bowel Disease Anti-TNFα Inadequate Response MechanismsSemantic proximity Read ↗

Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study.Semantic proximity Read ↗

Synovial fibroblast niche shapes the efficacy–safety dynamics of JAK inhibition in rheumatoid arthritisSemantic proximity Read ↗

Multitrait genome-wide analyses identify new susceptibility loci and candidate drugs to primary sclerosing cholangitis.Semantic proximity Read ↗

Impact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19.Semantic proximity Read ↗

Intergenic risk variant rs56258221 skews the fate of naive CD4+ T cells via miR4464-BACH2 interplay in primary sclerosing cholangitis.Semantic proximity Read ↗

Identification of new susceptibility loci associated with rheumatoid arthritis.Semantic proximity Read ↗

A disease-associated gene desert directs macrophage inflammation through ETS2Semantic proximity Read ↗

Integration of Known DNA, RNA and Protein Biomarkers Provides Prediction of Anti-TNF Response in Rheumatoid Arthritis: Results from the COMBINE StudySemantic proximity Read ↗

Sarcopenia and immune-mediated inflammatory diseases: Evaluating causality and exploring therapeutic targets for sarcopenia through Mendelian randomization.Semantic proximity Read ↗

Upadacitinib: Mechanism of action, clinical, and translational scienceSemantic proximity Read ↗

rs657075 (CSF2) Is Associated with the Disease Phenotype (BAS-G) of Ankylosing Spondylitis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.